Help us improve our site.
Precancerous conditions of the testicle
Intratubular germ cell neoplasia, unclassified (IGCNU), is a precancerous condition that can develop in the testicle. It is also called carcinoma in situ or testicular intraepithelial neoplasia.
IGCNU is when germ cells in the seminiferous tubules change so they are no longer normal. The germ cells look like cancer cells, but they aren’t behaving like cancer cells yet. This means that they are not growing into the surrounding tissues, or they are non-invasive. But there is a higher chance that these changes will become testicular cancer.
IGCNU can develop into any type of germ cell tumour. About 50% of men with a germ cell tumour in one testicle will have IGCNU in the other testicle.
The following risk factors increase your chance of developing IGCNU:
- personal history of testicular cancer
- undescended testicle, or cryptorchidism
- a birth defect where the genitals do not look normal (called ambiguous genitalia)
IGCNU usually doesn’t cause any symptoms because a lump does not form. It may cause fertility problems in some cases.
IGCNU is usually found during an orchiectomy, which is surgery to remove one or both testicles because of testicular cancer. It can also be found when the doctor is looking for the cause of other problems.
IGCNU is diagnosed with a biopsy, which means removing tissue from the testicle so it can be examined under a microscope. A biopsy can be done as part of an orchiectomy. A biopsy may also be done to find the reason for other problems, such as infertility.
Experts are trying to find the best ways to treat IGCNU. Currently, there are no standard treatments. Treatment is based on risk factors and each man’s needs and preferences.
Treatment options for IGCNU may include:
- watchful waiting
- radiation therapy
Even though we are high school students, we were able to raise so much money for the Canadian Cancer Society. It just goes to show what can happen when a small group of people come together for a great cause.
Clinical trial discovery improves quality of life
A clinical trial led by the Society’s NCIC Clinical Trials group found that men with prostate cancer who are treated with intermittent courses of hormone therapy live as long as those receiving continuous therapy.